August 21st 2025
Beyond administering CAR T-cell therapy and bispecifics, oncology nurses must apply proactive, supportive care and an understanding of complex treatments.
Cilta-Cel Delivers High Response Rates in Early Relapsed/Refractory Myeloma, According to Data Leak
April 25th 2023Data that was leaked from a 2023 EHA Hybrid Congress Abstracts demonstrated that ciltacabtagene autoleucel reduced the risk of disease progression in patients with relapsed/refractory multiple myeloma.
Oncology Financial Navigator Interventions Provide Benefits to Patients With Hematologic Cancers
March 30th 2023To evaluate the prevalence of financial toxicity and observe the effect of Coverage and Cost-of-Care Links, a program providing financial navigation, investigators initiated a nonrandomized study.
Smith Discusses Importance of Adherence When Integrating Pirtobrutinib Into Clinical Practice
March 7th 2023Leslie Smith, DNP, RN, APRN-CNS, BMTCN, AOCNS, highlights the pirtobrutinib approval for mantle cell lymphoma, and what she anticipates will encompass best nursing practices with the newly approved agent.
Magrolimab Plus Rituximab/Chemo Delivers Responses in Relapsed/Refractory DLBCL
February 3rd 2023At 11.3 months of follow-up, magrolimab, rituximab, gemcitabine, and oxaliplatin yielded an overall response rate of 51.5%, including a complete response rate of 39.4%, among patients with relapsed or refractory diffuse large B-cell lymphoma.